Find Reports

Select Report Type

Reimbursement Review

Displaying 51 - 75 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
remdesivir	Veklury	remdesivir	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input Stakeholder feedback on Draft Recommendation	COVID-19 in non-hospitalized patients	Reimburse with clinical criteria and/or conditions	Complete	Mar 1, 2024	Aug 16, 2024	SR0834-000
remdesivir	Veklury	remdesivir	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	COVID-19 in hospitalized patients	Reimburse with clinical criteria and/or conditions	Complete	Mar 1, 2024	Aug 16, 2024	SR0833-000
inclisiran	Leqvio	inclisiran	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Primary hypercholesterolemia	Reimburse with clinical criteria and/or conditions	Complete	Sep 19, 2023	Aug 15, 2024	SR0791-000
cariprazine	Vraylar	cariprazine	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Schizophrenia	Reimburse with clinical criteria and/or conditions	Complete	Dec 20, 2023	Aug 15, 2024	SR0827-000
cabotegravir	Apretude	cabotegravir	Recommendation and Reason Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	HIV-1 infection, pre-exposure prophylaxis	Reimburse with clinical criteria and/or conditions	Complete	Feb 1, 2024	Aug 14, 2024	SR0825-000
etrasimod	Velsipity	etrasimod	Recommendation and Reason Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Ulcerative colitis	Reimburse with clinical criteria and/or conditions	Complete	Feb 5, 2024	Aug 14, 2024	SR0795-000
evolocumab	Repatha	evolocumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Primary hyperlipidemia	Reimburse with clinical criteria and/or conditions	Complete	Nov 29, 2023	Aug 8, 2024	SR0821-000
Pembrolizumab	N/A	Pembrolizumab	Recommendation and Reason Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input	Melanoma (Skin)	Reimburse with clinical criteria and/or conditions	Complete	Oct 16, 2023	Aug 1, 2024	PX0346-000
Nivolumab and Ipilimumab	N/A	Nivolumab and Ipilimumab	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic combined Report Stakeholder Input	Melanoma (Skin)	Reimburse with clinical criteria and/or conditions	Complete	Oct 16, 2023	Aug 1, 2024	PX0347-000
Nab-paclitaxel	N/A	Nab-paclitaxel	Recommendation and reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input	Solid tumours	Reimburse with clinical criteria and/or conditions	Complete	Oct 16, 2023	Jul 24, 2024	PX0348-000
relugolix	Orgovyx	relugolix	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation Patient and Clinician Group input	Advanced prostate cancer	Reimburse with clinical criteria and/or conditions	Complete	Nov 14, 2023	Jul 22, 2024	PC0342-000
atogepant	Qulipta	atogepant	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Migraine, prevention	Reimburse with clinical criteria and/or conditions	Complete	Dec 21, 2023	Jul 15, 2024	SR0817-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Biliary tract carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Dec 7, 2023	Jul 11, 2024	PC0344-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Gastric or gastroesophageal junction adenocarcinoma	Reimburse with clinical criteria and/or conditions	Complete	Nov 22, 2023	Jun 26, 2024	PC0343-000
aflibercept 8mg/0.07mL	Eylea HD	aflibercept 8mg/0.07mL	Recommendation and Reasons Patient and Clinician Group input Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	diabetic macular edema	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2023	Jun 5, 2024	SR0813-000
aflibercept 8mg/0.07mL	Eylea HD	aflibercept 8mg/0.07mL	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	macular degeneration, age related	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2023	Jun 5, 2024	SR0812-000
elranatamab	Elrexfio	elranatamab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Relapsed or refractory multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Nov 9, 2023	May 31, 2024	PC0315-000
epcoritamab	Epkinly	epcoritamab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Relapsed or refractory diffuse large B-cell lymphoma	Time-limited reimbursement recommendation	Complete	Nov 14, 2023	May 31, 2024	PC0334-000
nivolumab	Opdivo	nivolumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Stage IIB or IIC melanoma, adjuvant	Reimburse with clinical criteria and/or conditions	Complete	Nov 6, 2023	May 29, 2024	PC0339-000
insulin icodec	Awiqli	insulin icodec	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Diabetes mellitus, type 2	Reimburse with clinical criteria and/or conditions	Complete	Oct 18, 2023	May 17, 2024	SR0790-000
bimekizumab	Bimzelx	bimekizumab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 19, 2023	May 16, 2024	SR0809-000
bimekizumab	Bimzelx	bimekizumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Psoriatic arthritis	Reimburse with clinical criteria and/or conditions	Complete	Oct 5, 2023	May 15, 2024	SR0803-000
metreleptin	Myalepta	metreleptin	Recommendations and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Leptin deficiency in lipodystrophy	Reimburse with clinical criteria and/or conditions	Complete	Jul 25, 2023	May 9, 2024	SR0784-000
avatrombopag	Doptelet	avatrombopag	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Chronic immune thrombocytopenia (ITP)	Do not reimburse	Complete	Feb 3, 2022	May 8, 2024	SR0721-000
tralokinumab	Adtralza	tralokinumab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	atopic dermatitis (AD)	Do not reimburse	Complete	Jun 5, 2023	May 8, 2024	SR0787-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 51 - 75 of 600

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis		BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis	Oct 21, 2024	Rapid Review	Completed	RC1549-000
Re-treatment With Immune Checkpoint Inhibitors: Utilization Analysis			Oct 16, 2024	Technology Review	In Progress	HC0093-000
The Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia			Oct 10, 2024	Observational Study	Active	OS0011-000
Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer		Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer	Oct 4, 2024	Summary with Critical Appraisal	Completed	RC1550-000
Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant		Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant	Oct 2, 2024	Rapid Review	Completed	RC1553-000
Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18 to 64 Years		Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18…	Sep 26, 2024	Technology Review	Completed	HE0054-000
Short-Cycle Autoclave Sterilization of Instruments in Same-Day Ophthalmic Surgeries		Short-Cycle Autoclave Sterilization of Instruments in Same-Day Ophthalmic Surgeries	Sep 25, 2024	Rapid Review	Completed	RC1547-000
Continuously Diffused Therapy for Wound Healing	To inform decisions about continuously diffused oxygen (CDO) therapy for wound healing, we identified and summarized literature comparing the clinical effectiveness and cost-effectiveness of CDO therapy versus conventional wound care.	Continuously Diffused Therapy for Wound Healing	Sep 20, 2024	Rapid Review	Completed	RC1548-000
Review of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update		Review of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update	Sep 17, 2024	Rapid Review	Completed	RC1541-000
Thrombopoietin Receptor Agonists as Second-Line Treatment in Children With Ongoing Immune Thrombocytopenia		Thrombopoietin Receptor Agonists as Second-Line Treatment in Children With Ongo…Protocol List of included studies	Sep 12, 2024	Technology Review	Completed	HC0033-000
Methoxyflurane Inhalation as an Analgesic for Minor Gynecological, Ambulatory, or Emergency Procedures		Methoxyflurane Inhalation as an Analgesic for Minor Gynecological, Ambulatory, or Emergency Procedures	Sep 11, 2024	Rapid Review	Completed	RC1545-000
Retesting Intervals for Tryptase		Retesting Intervals for Tryptase	Sep 11, 2024	Rapid Review	Completed	RC1546-000
Drug Shortages and Patient Harms	The objective of our report is to summarize the evidence on patient outcomes associated with supply chain disruptions of pharmaceuticals and vaccines.	Drug Shortages and Patient Harms	Sep 9, 2024	Technology Review	Completed	HC0072-000
Safety of Ozempic for Type II Diabetes		Final Report Summary Report	Sep 6, 2024	Observational Study	Completed	OS0005-000
An Inventory of Rare Disease Registries in the Canadian Landscape		An Inventory Report of Rare Disease Registries in the Canadian Landscape	Aug 29, 2024	Environmental Scan	Completed	CP0033-000
Alternate level of care (ALC)			Aug 26, 2024	Optimal Use	Active	OP0557-000
Review of Guidelines on Clonidine for Various Indications		Review of Guidelines on Clonidine for Various Indications	Aug 19, 2024	Rapid Review	Completed	RC1543-000
Efficacy and Safety of Treatment Options for Uncomplicated Gonococcal Infections		Efficacy and Safety of Treatment Options for Uncomplicated Gonococcal Infections Summary Report	Aug 19, 2024	Rapid Review with Expert Input	Completed	RD0070-000
The Canadian Medical Imaging Inventory: 2022–2023		Canadian Medical Imaging Inventory 2022– 2023: CT Canadian Medical Imaging Inventory 2022– 2023: MRI Canadian Medical Imaging Inventory 2022– 2023: PET-CT and PET-MRI Canadian Medical Imaging Inventory 2022–2023: SPECT and SPECT-CT Canadian Medical Imaging Inventory 2022–2023: Provincial and Territorial Overvi…Canadian Medical Imaging Inventory 2022–2023: The Medical Imaging Team Canadian Medical Imaging Inventory 2022– 2023: Methods The Canadian Medical Imaging Inventory 2022–2023 - Evidence Preview	Aug 13, 2024	Technology Review	Completed	HC0024-000
Evidence Review of Treatment Options for Uncomplicated Gonococcal Infections		Final Report Summary Report	Aug 6, 2024	Technology Review	Completed	RE0046-000
Re-Treatment With Immune Checkpoint Inhibitors		Final Report	Aug 6, 2024	Summary with Critical Appraisal	Completed	RC1544-000
Drug Shortages in Canada		Final Report	Jul 31, 2024	Environmental Scan	Completed	ES0381-000
Opioid Analgesics to Treat Chronic Noncancer Pain among Patients Prescribed Opioid Agonist Therapy or With Opioid Use Disorder	Our systematic review examined 5 observational studies on the safety of opioid analgesics alone or with opioid agonist therapy for chronic pain in patients with opioid use disorder or a history of opioid use disorder.	Summary Report Final Report Supplemental Document Project Protocol	Jul 23, 2024	Systematic Review	Completed	RE0045-000
Auditory Verbal Therapy for Children with Hearing Loss		Auditory Verbal Therapy for Children with Hearing Loss	Jul 19, 2024	Rapid Review	Completed	RC1542-000
Optimizing ultrasound booking schedules			Jul 16, 2024		In Progress	CM0021-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 51 - 75 of 110

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
2022 Health Technology Trends to Watch	2022 Health Technology Trends to Watch	Mar 16, 2022	Roundup	Completed	ER0012-000
Artificial Intelligence for the Prediction of Sepsis in Adults	Artificial Intelligence for the Prediction of Sepsis in Adults	Mar 14, 2022	Health Technology Update	Completed	EN0034-000
Vacuum-Induced Uterine Tamponade for Postpartum Hemorrhage	Vacuum-Induced Uterine Tamponade for Postpartum Hemorrhage	Mar 8, 2022	Health Technology Update	Active	EN0035-000
Emerging Drugs for Amyotrophic Lateral Sclerosis	Emerging Drugs for Amyotrophic Lateral Sclerosis	Mar 1, 2022	Emerging Health Technologies	Completed	EH0100-000
Emerging Drugs for Generalized Myasthenia Gravis	Horizon Scan	Feb 24, 2022	Emerging Health Technologies	Completed	EH0099-000
An Overview of Smartphone Apps	Horizon Scan	Feb 22, 2022	Emerging Health Technologies	Completed	EH0098-000
Renal Denervation for People with Hypertension	Health Technology Update	Jan 17, 2022	Health Technology Update	Completed	EN0038-000
Self-Sampling Devices for HPV Testing	Horizon Scan	Dec 21, 2021	Emerging Health Technologies	Completed	EH0101-000
An Overview of Emerging Point-of-Care Tests for Differentiating Bacterial and Viral Infections	An Overview of Emerging Point-of-Care Tests for Differentiating Bacterial and V…	Dec 14, 2021	Emerging Health Technologies	Completed	EH0097-000
Adaptive Deep Brain Stimulation for the Treatment of Parkinson Disease and Essential Tremor	Adaptive Deep Brain Stimulation for the Treatment of Parkinson Disease and Esse…	Dec 2, 2021	Health Technology Update	Completed	EN0036-000
Neuromodulation Technologies for the Treatment of Alzheimer Disease	Neuromodulation Technologies for the Treatment of Alzheimer Disease	Sep 27, 2021	Emerging Health Technologies	Completed	EH0095-000
An Overview of Post‒COVID-19 Condition (Long COVID)	An Overview of Post‒COVID-19 Condition (Long COVID)	Sep 24, 2021	Emerging Health Technologies	Completed	EH0096-000
Pharyngeal Electrical Stimulation Device for the Treatment of Dysphagia Associated With Neurologic Conditions	Pharyngeal Electrical Stimulation Device for the Treatment of Dysphagia Associ…	Sep 22, 2021	Health Technology Update	Completed	EN0030-000
Barricaid Spinal Implant Device	Horizon Scan Newsletter	Aug 16, 2021	Health Technology Update	Completed	EN0032-000
Breath Tests for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2	Breath Tests for the Detection of Severe Acute Respiratory Syndrome Coronavirus…	Aug 6, 2021	Health Technology Update	Completed	EN0039-000
Portable Neuromodulation Stimulator for chronic balance or gait impairment	Horizon Scan Newsletter	Aug 6, 2021	Health Technology Update	Completed	EN0031-000
Combined Testing for Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza	Combined Testing for Severe Acute Respiratory Syndrome Coronavirus 2 and Influe…	Jun 30, 2021	Health Technology Update	Completed	EN0029-000
Wearable Respiratory Sensor for the Detection of Opioid-Induced Respiratory Depression	EN0028 Respmeter Newsletter Final.pdf	Jun 15, 2021	Health Technology Update	Completed	EN0028-000
Direct to Patient Virtual Visits	An Overview of Direct-to-Patient Virtual Visits in Canada	Jun 4, 2021	Emerging Health Technologies	Completed	EH0091-000
Framework for Drugs for Rare Diseases	es0355-drugs-for-rare-diseases-pw.pdf	May 6, 2021	Environmental Scan	Completed	ES0355-000
2021 Health Technology Trends to Watch	ER0011 Horizon Scanning 2021 Tech Trends v8.0.pdf	Feb 4, 2021	Roundup	Completed	ER0011-000
Rapid Point-of-Care Testing for COVID-19	Rapid Point-of-Care Testing for COVID-19	Dec 18, 2020	Emerging Health Technologies	Complete	RB1536-000 - EH0093-000
Serological Tests for COVID-19	Serological Tests for COVID-19 The Role of Different Types of Tests in the COVID-19 Pandemic	Dec 18, 2020	Emerging Health Technologies	Completed	EH0085-000
Connected Devices to Support Remote Examination and Diagnosis in Primary Care and Specialty Care		Dec 10, 2020	Emerging Health Technologies	Completed	EH0088-000
COVID-19 Testing: A Summary of Testing Methods	COVID-19 Testing: A Summary of Testing Methods	Dec 9, 2020	Emerging Health Technologies	Completed	EH0090-000

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 51 - 75 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
relugolix, estradiol, and norethindrone acetate	Patient and Clinician Group Input	Apr 11, 2025	Reimbursement Review		Active	SR0885-000
Dupilumab	Patient and Clinician Group input	Apr 11, 2025	Reimbursement Review		Active	SR0870-000
daridorexant	Patient and Clinician Group input	Apr 11, 2025	Reimbursement Review		Active	SR0862-000
fecal microbiota	Patient and Clinician Group Input	Apr 11, 2025	Reimbursement Review		Active	SR0850-000
olopatadine hydrochloride and mometasone	Draft Recommendation Patient and Clinician Group input	Apr 11, 2025	Reimbursement Review		Active	SR0848-000
dabrafenib trametinib	Draft Recommendation and Reasons Draft Responses to the Questions from the Drug Programs Draft Clinical & Pharmacoeconomic Combined Report Draft Combined Report Supplemental Material Proposed Scope	Apr 11, 2025	Reimbursement Review		Active	PX0375-000
Dabrafenib trametinib	Draft Recommendations & Reasons Draft Responses to the Questions from the Drug Programs Draft Clinical & Pharmacoeconomic Combined Report Draft Combined Report Supplemental Material Proposed Scope	Apr 11, 2025	Reimbursement Review		Active	PX0373-000
regorafenib	Draft Recommendation Draft Responses to the Questions from the Drug Programs Draft Clinical & Pharmacoeconomic Combined Report Draft Combined Report Supplemental Material Proposed Scope	Apr 11, 2025	Reimbursement Review		Active	PX0374-000
polatuzumab vedotin	Patient and Clinician Group Input	Apr 11, 2025	Reimbursement Review		Active	PC0397-000
mirvetuximab soravtansine	Patient and Clinician Group Input	Apr 11, 2025	Reimbursement Review		Active	PC0394-000
amivantamab	Patient and Clinician Group input	Apr 11, 2025	Reimbursement Review		Active	PC0393-000
pembrolizumab	Draft Recommendation Patient and Clinician Group Input	Apr 11, 2025	Reimbursement Review		Active	PC0385-000
isatuximab	Patient and Clinician Group input	Apr 11, 2025	Reimbursement Review		Active	PC0378-000
durvalumab	Patient and Clinician Group input	Apr 11, 2025	Reimbursement Review		Active	PC0372-000
lemborexant		Apr 11, 2025	Reimbursement Review		Received	SR0895-000
bulevirtide		Apr 11, 2025	Reimbursement Review		Received	SR0881-000
Cabozantinib for 2L Renal Cell Carcinoma	Cabozantinib for 2L Renal Cell Carcinoma	Apr 9, 2025	Health Technology Review	Rapid Review	Completed	RC1573-000
Nivolumab and ipilimumab		Apr 9, 2025	Reimbursement Review		Pending	PC0420-000
ruxolitinib	Draft Recommendation	Apr 9, 2025	Reimbursement Review		Active	SR0807-000
nemolizumab	Patient and Clinician Group input	Apr 9, 2025	Reimbursement Review		Active	SR0861-000
pasireotide	Draft Recommendations & Reasons Patient and Clinician Group input	Apr 9, 2025	Reimbursement Review		Active	SR0859-000
teprotumumab	Patient and Clinician Group Input	Apr 9, 2025	Reimbursement Review		Active	SR0853-000
acalabrutinib		Apr 9, 2025	Reimbursement Review		Active	PC0413-000
lazertinib and amivantamab	Patient and Clinician Group input	Apr 9, 2025	Reimbursement Review		Active	PC0392-000
pegunigalsidase alfa	Patient and Clinician Group Input	Apr 8, 2025	Reimbursement Review		Received	SR0872-000